Top

Biological Sample Preparation & Handling

Active

Federal

Response Deadline09/08/2026, 07:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

General Info

Agency

Department Of Health And Human Services → Advanced Research Projects Agency For Health (arpa-H)View Agency

NAICS

621790

Place of Performance

77416, DC, USA

Set-Aside

NONE

Documents

This scope was carved out of 75N992-26-SS-106.

The full solicitation package (1 document), including the RFP, is on the prime solicitation, not on this scope.

View the prime solicitation

Py-GC/MS for Micro- and Nanoplastic Analysis

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PostedAug 24

subcontract

Response DeadlineSep 8

Submission deadline

Response Deadline

09/08/2026, 07:00:00 PM UTCin 15 days

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

AgencyDepartment Of Health And Human Services → Advanced Research Projects Agency For Health (arpa-H)

ContactsNo contacts available

OfficeN/A

Organization / Agency

Department Of Health And Human Services → Advanced Research Projects Agency For Health (arpa-H)

View Agency Profile

Office AddressN/A

ContactsNo contact information available

Full Description

Prepare and handle human biological samples (blood, urine, tissue) for micro- and nanoplastics analysis, including homogenization, lipid removal, and matrix isolation while preserving sample integrity and preventing cross-contamination.

More opportunities from Department Of Health And Human Services → Advanced Research Projects Agency For Health (arpa-H)

Same awarding agency

NAICS: 541690

New

Federal

Quality Assurance & Data Validation Services

Other Scientific and Technical Consulting Services

POSTED

DEADLINE

Polymer Reference Standards & Calibration Materials Supply

Other Chemical and Allied Products Merchant Wholesalers

POSTED

DEADLINE

ISO-7 Cleanroom Facility Operations & Maintenance

Testing Laboratories and Services

POSTED

DEADLINE

Py-GC/MS Method Development & Validation

Research and Development in Nanotechnology

POSTED

DEADLINE

Py-GC/MS for Micro- and Nanoplastic Analysis

Solicitation # 75N992-26-SS-106

The Advanced Research Projects Agency for Health (ARPA-H) Health Science Futures Office has issued a sources sought notice to evaluate industry interest and capabilities regarding specialized analytical services. The agency is seeking organizations with the expertise to provide gold-standard Pyrolysis-gas chromatography/mass spectrometry (Py-GC/MS) analysis. This technical requirement focuses on the detection and analysis of micro- and nanoplastics (MNPs) within various biological samples, including blood, urine, and tissue. This solicitation, identified by number 75N992-26-SS-106, serves as a market research tool to identify vendors with relevant experience in high-precision chemical analysis for health science applications. Interested parties must submit their responses by the deadline of September 8, 2026. The procurement falls under NAICS code 334516 and is managed by the Department of Health and Human Services.

Analytical Laboratory Instrument Manufacturing

POSTED

DEADLINE

Fast Assessment of Solutions, Therapeutics, Pharmaceuticals, and SupplieS (FASTPASS) Innovative Solutions Opening

Solicitation # ARPA-H-SOL-26-160

The Advanced Research Projects Agency for Health (ARPA-H) has issued solicitation ARPA-H-SOL-26-160 for the Fast Assessment of Solutions, Therapeutics, Pharmaceuticals, and SupplieS (FASTPASS) program. This initiative seeks to develop an innovative, AI-enabled system capable of performing near real-time, non-destructive screening of pharmaceutical products and their inputs. The technology is intended to inspect items through their packaging at critical supply-chain nodes and ports of entry to enhance security and efficiency. Interested parties must submit their responses by the deadline of November 10, 2026. The solicitation is managed by the Department of Health and Human Services under the ARPA-H agency, with the primary point of contact being the FASTPASS Team. This opportunity falls under NAICS code 541715 and is categorized as an innovative solutions opening aimed at advancing pharmaceutical supply chain integrity through cutting-edge technological integration.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Fast Assessment of Solutions, Therapeutics, Pharmaceuticals, and SupplieS (FASTPASS) Proposers' Day

Solicitation # ARPA-H-SN-26-160

The Advanced Research Projects Agency for Health (ARPA-H) Scalable Solutions Office is hosting a Proposers' Day for the Fast Assessment of Solutions, Therapeutics, Pharmaceuticals, and SupplieS (FASTPASS) program. This hybrid event is scheduled for Thursday, September 10, 2026, from 9:00 am to 5:00 pm Eastern Time. The initiative falls under the Innovative Solutions Opening (ISO) and is managed by the Department of Health and Human Services. Interested parties should note that the response deadline for this special notice is September 4, 2026, at 4:00 pm. The solicitation, identified by number ARPA-H-SN-26-160, is categorized under NAICS code 541715. For further inquiries or technical details, the FASTPASS Team can be reached via email at FASTPASS@ARPA-H.GOV.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Advanced Research Projects Agency for Health (ARPA-H) Small Business Innovation Research (SBIR)/Small Business Technology Transfer (STTR) Program

Solicitation # 7599226SN106

The Advanced Research Projects Agency for Health (ARPA-H) is soliciting proposals through a Broad Agency Announcement for its Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, targeting small business concerns with expertise in innovative biomedical and health technologies. Eligible small businesses must be organized for profit, headquartered and primarily operating in the United States, and have no more than 500 employees, including affiliates, with majority ownership held by U.S. citizens or permanent residents. Alternatively, ownership may be held by multiple venture capital, hedge fund, or private equity firms, provided no single entity owns more than 50% of the concern. Proposers must be registered in SAM.gov with a Unique Entity Identifier and must also be certified in the SBA Company Registry. The solicitation is a Total Small Business Set-Aside under FAR 19.5, with NAICS code 541715, and all submissions must be made via the ARPA-H Solutions site. A critical deadline for Stage 1 Solution Summaries has been extended to July 17, 2026, and all proposals must include required documentation such as the Solution Summary Template, SBA Proof of Registration, Funding Agreement Certification, Foreign Disclosure Form, and VCOC Certification where applicable. Compliance with federal statutes, regulations, and security requirements, including the FAR 52.240-91 Security Prohibitions and Exclusions clause, is mandatory. The solicitation outlines seven open research topics, each targeting high-impact, high-risk innovations in women’s health, surgical adhesion, synthetic biology, endometriosis treatment, ARPA-H technology transition, autoimmune diagnostics, and neurosurgical robotics. Proposals must detail technical approaches, innovation, feasibility, and a clear path to commercialization and patient health outcomes. Evaluation is based on pass/fail gates for SBC eligibility and security risk via the HHS Due Diligence Program, followed by technical merit, novelty, team experience, and potential health impact. A fixed milestone-based payment structure applies, with Phase I awards typically lasting one year and disbursed in six installments tied to deliverables such as kickoff presentations, quarterly reports, draft and final reports, commercialization updates, invention disclosures, and lifecycle certifications. Required deliverables include a Task Description Document, GANTT chart, and detailed cost proposal using the official templates, with costs evaluated for reasonableness relative to scope. Proposers must mark proprietary information appropriately, bear all

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Pharmaceutical Supply and Dosing Strategy SupportThe contract pertains to the formulation, stability testing, and supply chain management of ibogaine or closely related compounds under an Investigational New Drug application to support clinical research initiatives. It requires the secure and compliant production of precise dosing formulations, adherence to rigorous pharmaceutical standards for compound stability, and robust logistics to ensure uninterrupted delivery of materials to authorized research sites. All activities must align with federal regulatory requirements governing investigational substances and be executed within a tightly controlled framework to maintain quality, safety, and chain-of-custody integrity throughout the supply lifecycle. The work is being solicited as a subcontract under the Advanced Research Projects Agency for Health, a division of the Department of Health and Human Services, with a primary focus on accelerating innovative therapeutic development. The solicitation is open for responses until October 15, 2026, and the North American Industry Classification System code 325412 indicates the scope involves pharmaceutical preparations manufacturing. Performance is expected to meet stringent federal standards for investigational drug supply, with no geographical restrictions specified on place of performance, allowing for flexible, secure, and scalable logistical execution across approved facilities.

Pharmaceutical Preparation Manufacturing

POSTED

DEADLINE

Phase III Clinical Development and Regulatory Transition PlanningThe contract titled Phase III Clinical Development and Regulatory Transition Planning focuses on strategic guidance for advancing a therapeutic or medical product from Phase II to Phase III clinical trials. It requires a detailed analysis of the regulatory pathway to ensure compliance with current and anticipated requirements from health authorities, as well as development of a long-term roadmap that integrates clinical, manufacturing, and commercialization goals. The work must account for global regulatory harmonization, risk mitigation strategies, and feasibility assessments for large-scale trial design and patient recruitment. This is a subcontract under the Advanced Research Projects Agency for Health, part of the Department of Health and Human Services, with a NAICS code of 541620 indicating management, scientific, and technical consulting services. The opportunity was posted on August 5, 2026, with a response deadline of October 15, 2026. There is no set-aside designation specified, and the place of performance is not defined, allowing flexibility in where the work is conducted. The contract emphasizes expert-level planning to de-risk the transition to pivotal trials and secure regulatory alignment for future approval and market access.

Environmental Consulting Services

POSTED

DEADLINE

Operational Execution of Multi-Site Clinical TrialsThe contract titled Operational Execution of Multi-Site Clinical Trials entails the comprehensive management and coordination of clinical trial operations across multiple geographic locations, with core responsibilities including the training and oversight of clinical staff, the implementation of patient recruitment strategies, and the accurate and timely collection of trial data. The scope demands a robust operational framework to ensure protocol adherence, regulatory compliance, and data integrity across all participating sites, requiring experienced personnel with demonstrated expertise in decentralized and multi-site clinical research environments. Issued as a subcontract under the Advanced Research Projects Agency for Health part of the Department of Health and Human Services, this opportunity is governed by NAICS code 541611 and requires proposals to be submitted by October 15, 2026. While the solicitation number and specific address details are not provided, performance is expected to occur across unspecified locations, indicating a nationwide or potentially international operational footprint. The contracting entity seeks entities capable of delivering scalable, efficient, and compliant clinical trial execution without direct oversight, emphasizing autonomy, quality control, and responsiveness in complex, distributed study settings.

Administrative Management and General Management Consulting Services

POSTED

DEADLINE

Therapeutic Set and Setting Protocol DevelopmentThe contract seeks the development of a comprehensive therapeutic set and setting protocol for the administration of ibogaine, focusing on the design of a safe, supportive, and clinically rigorous environment that optimizes patient outcomes. This includes the creation of structured psychological support systems, detailed patient preparation procedures, and integrated post-treatment protocols to ensure continuity of care and long-term therapeutic benefit. The protocol must be grounded in evidence-based practices and tailored to address the unique physiological and psychological demands of ibogaine therapy, with an emphasis on harm reduction, informed consent, and ethical standards. The work is being procured as a subcontract under the Advanced Research Projects Agency for Health, part of the Department of Health and Human Services, with a submission deadline of October 15, 2026. The project falls under NAICS code 621399, reflecting its focus on specialized medical services involving non-traditional therapeutic modalities. While the place of performance and point of contact details are not specified, the initiative aims to advance clinical frameworks for psychedelic-assisted therapies and requires a multidisciplinary approach integrating medical, psychological, and environmental design elements. Success will depend on delivering a replicable, scalable model that meets federal standards for safety, efficacy, and patient-centered care.

Offices of All Other Miscellaneous Health Practitioners

POSTED

19 days ago

DEADLINE

in about 2 months

View Details